TELA TELA Bio, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1561921 · Fiscal year ends 12/31
Financial factors as of 2026-03-31 (2026Q1), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.5%
TTM net income YoY8.3%
TTM EPS YoY41.5%
Revenue 3-yr CAGR21.5%
Net income 3-yr CAGR—
Margins
Gross margin67.3%
Operating margin-41.8%
Net margin-49.3%
FCF margin-37.4%
EBITDA margin-41.1%
Returns
ROE-616.6%
ROA-54.2%
ROIC (approx.)-192.9%
Asset turnover1.10x
Leverage & solvency
Liabilities / assets107.4%
Debt / equity—
Current ratio3.61x
Interest coverage-5.56x
Cash quality & payout
Operating cash flow / net income0.74x
Accruals ratio-13.8%
Payout ratio—
Capex / revenue0.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $18.96M | $19.29M | $19.06M | $20.87M | $20.69M | $20.20M | $18.52M | $17.65M |
| Cost of revenue | $6.56M | $5.25M | $6.44M | $7.02M | $6.62M | $6.00M | $5.91M | $6.33M |
| Gross profit | $12.31M | $13.94M | $12.52M | $13.76M | $13.97M | $14.11M | $12.51M | $11.22M |
| R&D expense | $1.60M | $2.72M | $2.34M | $2.13M | $2.35M | $2.20M | $2.54M | $2.03M |
| SG&A expense | $3.00M | $4.06M | $4.17M | $3.78M | $3.95M | $4.13M | $3.84M | $3.59M |
| Operating income | -$7.29M | -$9.28M | -$10.53M | -$6.65M | -$7.55M | -$9.08M | -$10.47M | -$8.35M |
| Interest expense | $2.10M | $2.08M | $2.05M | $1.64M | $1.20M | $1.19M | $1.22M | $1.28M |
| Pretax income | -$9.20M | -$11.20M | -$12.21M | -$8.90M | -$8.60M | -$9.89M | -$11.21M | -$9.35M |
| Income tax | $103,000 | $60,000 | $60,000 | $145,000 | $0 | $33,000 | $52,000 | — |
| Net income | -$9.30M | -$11.26M | -$12.27M | -$9.04M | -$8.60M | -$9.92M | -$11.26M | -$9.21M |
| EBITDA | -$7.12M | -$9.11M | -$10.36M | -$6.52M | -$7.40M | -$8.91M | -$10.30M | -$8.18M |
| EPS (basic) | -0.16 | -0.20 | -0.21 | — | -0.19 | -0.22 | -0.25 | — |
| EPS (diluted) | -0.16 | -0.20 | -0.21 | — | -0.19 | -0.22 | -0.25 | — |
| Weighted avg. shares (diluted) | 57.69M | 57.41M | 57.26M | — | 45.42M | 45.37M | 45.27M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $22.66M | $30.42M | $39.54M | $50.84M | $29.71M | $34.98M | $42.83M | $52.94M |
| Receivables | $9.27M | $9.64M | $9.71M | $10.35M | $11.27M | $11.24M | $10.56M | $10.10M |
| Inventory | $11.61M | $11.06M | $12.21M | $11.02M | $11.56M | $11.37M | $13.53M | $12.78M |
| Current assets | $44.60M | $54.49M | $64.30M | $75.58M | $56.05M | $60.74M | $69.75M | $78.07M |
| PP&E, net | $1.88M | $2.05M | $2.16M | $2.23M | $2.21M | $2.17M | $2.20M | $2.34M |
| Intangibles | $1.07M | $1.17M | $1.26M | $1.36M | $1.45M | $1.55M | $1.64M | $1.74M |
| Total assets | $49.49M | $59.74M | $69.89M | $81.42M | $61.59M | $67.54M | $77.25M | $86.57M |
| Current liabilities | $72.86M | $18.22M | $17.83M | $17.98M | $16.98M | $19.06M | $16.54M | $15.60M |
| Short-term debt | $56.30M | — | — | — | — | $3.33M | — | — |
| Long-term debt | — | $56.08M | $55.87M | $55.65M | $41.49M | $38.05M | $41.27M | $41.12M |
| Total debt | — | $56.08M | $55.87M | $55.65M | $41.49M | $41.38M | $41.27M | $41.12M |
| Total liabilities | $74.07M | $75.60M | $75.09M | $75.11M | $60.03M | $58.35M | $59.13M | $58.11M |
| Shareholders' equity | -$24.58M | -$15.87M | -$5.20M | $6.31M | $1.56M | $9.18M | $18.12M | $28.46M |
| Net debt | — | $25.66M | $16.32M | $4.81M | $11.78M | $6.41M | -$1.56M | -$11.81M |
| Shares outstanding | 45.14M | 44.83M | 44.77M | 44.54M | 40.34M | 39.58M | 39.55M | 39.40M |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.69M | -$9.38M | -$11.17M | -$4.87M | -$5.72M | -$7.91M | -$9.72M | -$7.53M |
| Capital expenditure | $7,000 | $59,000 | $119,000 | $91,000 | $211,000 | $114,000 | $32,000 | $264,000 |
| Free cash flow | -$8.70M | -$9.44M | -$11.29M | -$4.96M | -$5.93M | -$8.02M | -$9.76M | -$7.79M |
| Investing cash flow | $1.02M | $239,000 | $190,000 | $192,000 | $312,000 | $204,000 | $138,000 | -$190,000 |
| Financing cash flow | -$54,000 | -$15,000 | -$298,000 | $25.84M | $24,000 | -$3,000 | -$116,000 | $42.91M |
| Depreciation & amortization | $172,000 | $171,000 | $169,000 | $130,000 | $153,000 | $175,000 | $172,000 | $171,000 |
| Stock-based compensation | $626,000 | $613,000 | $816,000 | $812,000 | $955,000 | $985,000 | $1.04M | $1.09M |
Free plan shows the latest 8 periods; Pro shows all 33 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.